<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287179</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4650</org_study_id>
    <secondary_id>U1111-1242-5426</secondary_id>
    <secondary_id>2019-004234-42</secondary_id>
    <nct_id>NCT04287179</nct_id>
  </id_info>
  <brief_title>SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes</brief_title>
  <acronym>SUSTAIN SWITCH</acronym>
  <official_title>Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect and safety of 2 dose schedules for semaglutide (study&#xD;
      medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar&#xD;
      to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide&#xD;
      used to inject medicine under the skin, at a new dose of 2 mg. People taking part in the&#xD;
      study will take this medicine together with their current diabetes tablets other than&#xD;
      semaglutide. Participants will either get a start dose of 0.25 mg semaglutide or 0.50 mg&#xD;
      semaglutide, and the dose will be gradually increased to 2.0 mg semaglutide - which treatment&#xD;
      is decided by chance. Participants will inject semaglutide under the skin once a week, any&#xD;
      time of the day. When the dose reaches 2.0 mg semaglutide, participants will inject the&#xD;
      medicine with a new type of pen-injector. The study will last for about 24 weeks.&#xD;
      Participants will have 9 visits and 1 phone call with the study doctor. At 9 visits&#xD;
      participants will have blood taken and at 2 visits they will have eye examination done. Women&#xD;
      cannot take part if pregnant, breast-feeding or planning to become pregnant during the study&#xD;
      period. Women who are able to get pregnant will be checked 10 times for pregnancy via urine&#xD;
      tests.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In&#xD;
    parallel, the development of a new type of pen injector, which was an important part of the&#xD;
    trial, was ceased and thus this trial was cancelled.&#xD;
  </why_stopped>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">January 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Percent-point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent gastrointestinal adverse events</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse rate</measure>
    <time_frame>From baseline (week 0) to week 12</time_frame>
    <description>Beats per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From week 12 to week 17</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.50 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 0.25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once-weekly semaglutide administered subcutaneously (s.c., under the skin) with or without oral antidiabetics (OADs). Start dose 0.25 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.</description>
    <arm_group_label>Semaglutide 0.25 mg</arm_group_label>
    <arm_group_label>Semaglutide 0.50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 years or older at the time of signing informed consent.&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus at least 180 days prior to the day of&#xD;
             screening.&#xD;
&#xD;
          -  The need and willingness to change prior GLP-1 RA treatment to once-weekly semaglutide&#xD;
             s.c., as assessed by the investigator.&#xD;
&#xD;
          -  HbA1c of 6.5-10% (48-86 mmol/mol) (both inclusive).&#xD;
&#xD;
          -  Treatment with any therapeutic dose of GLP-1 RA other than once-weekly semaglutide&#xD;
             s.c., as defined in the local label, with or without OADs (metformin, DPP-4 inhibitor,&#xD;
             SU, glinide, thiazolidinedione, SGLT-2 inhibitor or alpha-glucosidase inhibitor). All&#xD;
             doses of antidiabetic treatments should have been stable for at least 90 days prior to&#xD;
             the day of the screening, at investigator's discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any medication for the indication of diabetes or obesity other than&#xD;
             stated in the inclusion criteria within the past 90 days prior to the day of&#xD;
             screening. However, short term insulin treatment for a maximum of 14 days prior to the&#xD;
             day of screening is allowed, as is prior insulin treatment for gestational diabetes.&#xD;
&#xD;
          -  Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less&#xD;
             than 30 mL/min/1.73 m2 according to Chronic Kidney Disease Epidemiology Collaboration&#xD;
             (CKDEPI) creatinine equation as defined by KDIGO 2012 classification.&#xD;
&#xD;
          -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by&#xD;
             a fundus examination performed within the past 90 days prior to screening or in the&#xD;
             period between screening and randomisation. Pharmacological pupil-dilation is a&#xD;
             requirement unless using a digital fundus photography camera specified for non-dilated&#xD;
             examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor &amp; Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockerau</city>
        <zip>2000</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Raisio</city>
        <zip>21200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials. com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

